SCHEMBL31358693

SCHEMBL31358693

Cc1cc(-c2ccc(C=C3C(=O)c4ccccc4C3=O)o2)ccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.58
KMT2A Q03164 10/20 0.57
MEN1 O00255 9/20 0.57
POLB P06746 10/20 0.55
MAPT P10636 9/20 0.55
ALDH1A1 P00352 8/20 0.55
L3MBTL1 Q9Y468 5/20 0.55
KDM4E B2RXH2 5/20 0.55
CTDSP1 Q9GZU7 4/20 0.55
PTPN5 P54829 2/20 0.55
PPM1G O15355 1/20 0.55
PTPN1 P18031 1/20 0.55
PTPN7 P35236 1/20 0.55
PTPRO Q16827 1/20 0.55
PTPN22 Q9Y2R2 1/20 0.55
PKM P14618 3/20 0.55
MAPK1 P28482 1/20 0.55
HPGD P15428 6/20 0.51
TDP1 Q9NUW8 6/20 0.50
APEX1 P27695 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358776 0.88 SIRT2 (0.62) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358844 0.82 MEN1 (0.60) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358872 0.82 KMT2A (0.60) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358688 0.82 HTRA2 (0.66) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358731 0.82 AKT1 (0.77) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358866 0.81 KMT2A (0.69) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358773 0.81 MEN1 (0.69) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358797 0.81 KMT2A (0.56) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358709 0.81 MEN1 (0.64) AKT1KMT2AMEN1POLBMAPT
SCHEMBL31358792 0.78 JAK2 (0.60) AKT1KMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 AKT1 194/4885KMT2A 1043/4885MEN1 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.